1052714-35-8

Basic information

• Product Name: 5-bromo-2-(2,6-difluorophenyl)pyrimidine-4-carboxylic acid
• Synonyms: 5-bromo-2-(2,6-difluorophenyl)pyrimidine-4-carboxylic acid
• CAS NO: 1052714-35-8
• Molecular Weight: 315.074
• Mol File: 1052714-35-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-(2,6-difluorophenyl)pyrimidine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(2,6-difluorophenyl)pyrimidine-4-carboxylic acid(1052714-35-8)
• EPA Substance Registry System: 5-bromo-2-(2,6-difluorophenyl)pyrimidine-4-carboxylic acid(1052714-35-8)

Safety Data

• Hazardous Substances Data: 1052714-35-8(Hazardous Substances Data)

Upstream product

• 488-11-9 mucobromic acid 
• 304867-43-4 2,6-difluorobenzimidamide hydrochloride 
• 766-38-1 mucobromic acid 

Downstream Products

• 1052714-32-5 5-amino-2-(2,6-difluorophenyl)pyrimidine-4-carboxylic acid 

Relevant articles and documents

Synthesis and Structure-Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases

Overexpression of PIM 1, 2, and 3 kinases is frequently observed in many malignancies. Previously, we discovered a potent and selective pan-PIM kinase inhibitor, compound 2, currently in phase I clinical trials. In this work, we were interested in replacing the amino group on the cyclohexane ring in compound 2 with a hydroxyl group. Structure-based drug design led to cellularly potent but metabolically unstable tetra-substituted cyclohexyl diols. Efforts on the reduction of Log D by introducing polar heterocycles improved metabolic stability. Incorporating fluorine to the tetra-substituted cyclohexyl diol moiety further reduced Log D, resulting in compound 14, a cellularly potent tetra-substituted cyclohexyl diol inhibitor with moderate metabolic stability and good permeability. We also describe the development of efficient and scalable synthetic routes toward synthetically challenging tetra-substituted cyclohexyl diol compounds. In particular, intermediate 36 was identified as a versatile intermediate, enabling a large-scale synthesis of highly substituted cyclohexane derivatives.

NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS

The present invention provides a compound of formula (A): I as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.